In 2025, the drug racked up net sales of $68.2 million, up from $60.1 million in the previous year.\ Full-year consolidated revenue increased by 16.8 per cent YoY to Rs 27,148 crore and net profit was Rs 5,456 crore
Mitophagy and DPN Silymarin (SBN), a sirtuin 1 activator, ameliorated sciatic nerve injury and oxidative damage in HG-induced mouse neuroblastoma cells (N2A) and STZ-induced SD rats and enhanced autophagy and mitophagy, which exerted some neuroprotective effects [167]
Developed by Eli Lilly, its molecular structure incorporates modified amino acids and a fatty acid side chain designed to extend its duration of action
North America Accounts for the Largest Share of the Market Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Latin America
All statistical analyses in the animal study were conducted using GraphPad Prism (version 5 for Windows